On April 5, 2022, Andrew Einhorn resigned as the Chief Financial Officer of RVL Pharmaceuticals plc (the “Company”), effective April 18, 2022. Mr. Einhorn currently serves as the Company’s principal financial officer and principal accounting officer. Mr. Einhorn’s decision did not result from a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Upon the effectiveness of Mr. Einhorn’s resignation, Brian Markison, Chief Executive Officer of the Company, will serve as the principal financial officer of the Company and Michael J. DePetris, who the Company engaged in January 2022 as a senior financial advisor and who, among other duties, assisted in preparing the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 30, 2022 (the “Annual Report”), will serve as the principal accounting officer of the Company.

Biographical information for Mr. Markison is available in the Annual Report under the heading “Information about our Executive Officers,” such information being incorporated herein by reference. Mr. DePetris, age 45, has served as a consultant to the Company since January 2022. Prior to beginning his consultancy with the Company, Mr. DePetris provided consultancy services most recently serving as Interim Controller for Univar Solutions Inc. (NYSE: UNVR), a global commodity and specialty chemical and ingredient distributor, from May 2021 to December 2021. From January 2021 to May 2021, Mr. DePetris served as a consultant for Vertex, Inc. (NASDAQ: VERX), a global provider of enterprise tax technology solutions. From 2007 to 2019, Mr. DePetris served in various roles of increasing responsibility at Avantor, Inc. (NYSE: AVTR) (formerly known as VWR International, LLC prior to its 2017 acquisition), a global provider of products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries, including as Vice President, Internal Audit from February 2016 to July 2018, Senior Vice President, Corporate Controller and Chief Accounting Officer from July 2018 to May 2019 and Senior Vice President and Chief Audit Executive from May 2019 to October 2019. Mr. DePetris is a Certified Public Accountant and holds a B.S. in Accounting from Saint Joseph’s University.

There is no family relationship between either Mr. Markison or Mr. DePetris and any director or executive officer of the Company. Mr. DePetris does not have a direct or indirect material interest required to be disclosed pursuant to Item 404(a) of Regulation S-K. The following related person transaction exists between Mr. Markison and the Company: Mr. Markison’s son, Ben Markison, serves as Director, Supply Chain at RVL Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company, and was paid approximately $150,000 for the year ended December 31, 2021.

The Company and RVL Holdings US LLC, a subsidiary of the Company, will enter into indemnification agreements with Mr. DePetris. The terms of Mr. DePetris's indemnification agreements with the Company and RVL Holdings US LLC are described in the Company's Registration Statement on Form S-1 (File No. 333-227357) (the "Registration Statement") and forms of such agreements were filed as Exhibit 10.24 and Exhibit 10.25, respectively, to the Registration Statement.